Private
Equity
Private equity firms operate in high-stakes environments where speed, execution, and risk directly impact investment returns. Our private equity lawyers advise sponsors and their portfolio companies throughout the investment life cycle. We help you execute transactions, manage risk, and address the legal, commercial, and regulatory issues that impact how your investment performs.
Our private equity team includes more than 150 lawyers in 20+ offices worldwide. Working across disciplines including finance, tax, antitrust, investment funds, restructuring, and litigation, we provide integrated guidance to support domestic and cross-border investments across industries and asset classes.
Energy & Infrastructure
Financial Services
Healthcare Private Equity
Private Equity Litigation
Evolving private equity strategies: A more selective, operational approach to value creation
At our European Health & Life Sciences Symposium 2026, conversations highlighted a market that remains active and attractive, but is materially more disciplined than in recent years. Across life sciences and healthcare, investors are operating in an environment shaped by valuation resets, constrained capital, higher financing costs, and less predictable exit pathways.
The result is not a retreat from the sector, but a shift in how value is assessed, created, and realised. Private equity remains highly engaged in therapeutics, medical technology, healthcare services and health tech, but the playbook is becoming more selective, more specialised, and more operational.
Read on for the takeaways from our Evolving Private Equity Strategies in Life Sciences & Healthcare” panel, moderated by McDermott Will & Schulte partners Johannes Eckhardt and Fabrice Piollet and bringing together Jean-François Billet, Managing Partner at Mérieux Partners, Edouard de Beaufort, Partner at Capza, Yonel Genin, Partner at Vivalto Partners and Samuel Levy, Co-founding Partner at Lauxera Capital Partners
We proudly assisted our clients in the following deals:
- Represented Main Capital a Netherlands-based fund, in its acquisitions of Wanko and FleetGO, which combined to form a new comprehensive logistics software group known as FleetGO Group.
- Represented Ambienta SGR S.p.A in the structuring and fundraising operations of Ambienta IV, which closed at a EUR 1.55 billion hard cap.
- Represented Ampersand Capital Partners in its investment with KKR in the business combination of Biosynth Carbosynth and Vivitide Inc.